Genetic disease company Vertex Pharmaceuticals has secured conditional marketing authorization for Casgevy (exagamglogene autotemcel) in Europe. 13 February 2024
Hearing loss specialist Sensorion has raised 50.5 million euros ($55 million), offering new shares at a price of 0.57 euro cents per share. 9 February 2024
Regenerative cell therapy specialist Neurona Therapeutics has raised $120 million in a financing round co-led by Viking Global Investors and Cormorant Asset Man 9 February 2024
Augmenting its strategic push into cell therapies, British pharma major AstraZeneca has announced that it will construct a state-of-the-art facility in Maryland 7 February 2024
OneChain Immunotherapeutics (OCI), a Spanish biotech focused on the development of CAR-T therapies for the treatment of oncologic diseases, has named Stefanos T 1 February 2024
A new cell and gene therapy initiative from the White House will launch with an initial focus on treatments for sickle cell disease (SCD). 1 February 2024
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.